Literature DB >> 30226342

Intraoperative dexmedetomidine attenuates stress responses in patients undergoing major spine surgery.

Myoung H Kim1,2, Ki Y Lee1,2, Sun J Bae1,2, Minju Jo1, Jin S Cho3,2.   

Abstract

BACKGROUND: Surgical stress induces stress hormone release and sympathetic hyperactivation, resulting in hemodynamic instability. Dexmedetomidine has sympatholytic and hemodynamic stabilizing effects. We investigated whether dexmedetomidine could attenuate stress responses in major spine surgery.
METHODS: In this prospective randomized study, 52 patients undergoing spine fusion surgery were randomized to placebo (N.=26) or to dexmedetomidine (N.=26) groups. Dexmedetomidine at a rate of 0.4 μg/kg/h or saline was infused, starting immediately after anesthetic induction and continuing until the end of surgery. Anesthesia was performed using desflurane and remifentanil in both groups. Serum levels of cortisol, epinephrine, norepinephrine, and interleukin-6 were assessed before surgery (T1), at the surgical incision (T2), at the bone procedure (T3), and one hour after surgery (T4). The hemodynamic variables and the autonomic nervous system balance evaluated with heart rate variability were assessed at the same time points.
RESULTS: Epinephrine and norepinephrine levels were higher over time in the control rather than in the dexmedetomidine group (P=0.001 and <0.001, respectively). The changes in cortisol, interleukin-6, and hemodynamics were similar between the groups. In the heart rate variability analysis, high-frequency decreased and low-frequency and low-frequency/high-frequency ratio increased during surgery in the control group, whereas they were maintained at the baseline level in the dexmedetomidine group. The changes in high-frequency, low-frequency, and the low-frequency/high-frequency ratio over time differed between the groups (P=0.009, 0.024, and 0.011, respectively).
CONCLUSIONS: Intraoperative dexmedetomidine administration reduced stress hormone release and maintained the balance of the autonomic nervous system. Dexmedetomidine could attenuate surgical stress response without untoward hemodynamic adverse events.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30226342     DOI: 10.23736/S0375-9393.18.12992-0

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  5 in total

1.  Effects of dexmedetomidine on stress hormones in patients undergoing cardiac valve replacement: a randomized controlled trial.

Authors:  Hanhua Wu; Jinqing Tang; Jiamei Pan; Ming Han; Huijun Cai; Hong Zhang
Journal:  BMC Anesthesiol       Date:  2020-06-06       Impact factor: 2.217

2.  Intraoperative dexmedetomidine attenuates norepinephrine levels in patients undergoing transsphenoidal surgery: a randomized, placebo-controlled trial.

Authors:  RyungA Kang; Ji Seon Jeong; Justin Sangwook Ko; Soo-Youn Lee; Jong Hwan Lee; Soo Joo Choi; Sungrok Cha; Jeong Jin Lee
Journal:  BMC Anesthesiol       Date:  2020-05-02       Impact factor: 2.217

3.  Effects of Perioperative Dexmedetomidine on Immunomodulation in Uterine Cancer Surgery: A Randomized, Controlled Trial.

Authors:  Jin Sun Cho; Kieun Seon; Min-Yu Kim; Sang Wun Kim; Young Chul Yoo
Journal:  Front Oncol       Date:  2021-11-16       Impact factor: 6.244

4.  Immunomodulatory Effects of Perioperative Dexmedetomidine in Ovarian Cancer: An In Vitro and Xenograft Mouse Model Study.

Authors:  Seokyung Shin; Ki Jun Kim; Hye Jeong Hwang; Sewon Noh; Ju Eun Oh; Young-Chul Yoo
Journal:  Front Oncol       Date:  2021-10-07       Impact factor: 6.244

5.  Effect of dexmedetomidine supplementation for thoracoscopic surgery: a meta-analysis of randomized controlled trials.

Authors:  Chengjun Song; Quan Lu
Journal:  J Cardiothorac Surg       Date:  2022-04-06       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.